Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Article

C421A Polymorphism in the Human Breast Cancer Resistance Protein Gene Is Associated with Low Expression of Q141K Protein and Low-Level Drug Resistance 1 Supported in part by grants from the Ministry of Education, Culture, Sports, Science and Technology, the Ministry of Health, Labour and Welfare, Japan, and the Virtual Research Institute of Aging of Nippon Boehringer Ingelheim.1

Yasuo Imai, Minoru Nakane, Kumie Kage, Satomi Tsukahara, Etsuko Ishikawa, Takashi Tsuruo, Yoshio Miki and Yoshikazu Sugimoto
Yasuo Imai
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Minoru Nakane
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kumie Kage
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Satomi Tsukahara
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Etsuko Ishikawa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takashi Tsuruo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoshio Miki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoshikazu Sugimoto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published June 2002
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Western blot analysis of BCRP expression in 12 tumor cell lines of the NCI anticancer drug screening. Western blot analysis was performed under a nonreducing condition, so that the dimeric form BCRP was observed as a band at ∼140 kDa. A serial dilution of PA/WT cells (PA317 cells transfected with wild-type BCRP cDNA) were used as a positive control. Six cell lines in the top lane showed considerably high BCRP expression.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Identification of C421A polymorphism in A549 cells. A, wild-type BCRP cDNA. The entire coding region of BCRP mRNA was amplified by RT-PCR, subcloned, and sequenced. The 421st base is cytosine (arrow). B, C421A BCRP cDNA. The 421st base was changed from cytosine to adenine (arrow) in five of eight clones analyzed. C, direct genomic sequencing of the 421st nucleotide. The mutation was confirmed by genomic DNA analysis. Exon 5 covering the 421st nucleotide was amplified by PCR and directly sequenced, demonstrating both the wild-type and C421A alleles (arrow).

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Expression analysis of mutant BCRP transfectants. PA317 cells transfected with wild-type, G34A, C421A, and 944–949-deleted BCRP cDNAs were termed PA/WT, PA/V12M, PA/Q141K, and PA/Δ315-6, respectively. A, Western blotting of PA317 cells transfected with mutant BCRP cDNA in pHaL-IRES-DHFR plasmid. Twenty μg of protein was loaded in each lane. Top panel, Western blot analysis processed under a nonreducing condition. BCRP dimer was detected as a band at ∼140 kDa. Bottom panel, Western blot analysis processed under a reducing condition. BCRP monomer was detected as a band at ∼70 kDa. B, top panel, Northern blot analysis of PA317 cells and BCRP transfectants. Twenty μg of total RNA was loaded in each lane of the agarose-formaldehyde gel and transferred to Hybond-N+. The blot was hybridized with a BCRP cDNA probe. Bottom panel, ethidium bromide staining of total RNA after electrophoresis. 28S and 18S indicate 28S and 18S ribosomal RNA, respectively.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Growth inhibition assay of mutant BCRP-transfected PA317 cells. PA317 cells transfected with wild-type, G34A, C421A, and 944–949-deleted BCRP cDNAs were termed PA/WT, PA/V12M, PA/Q141K, and PA/Δ315-6, respectively. A, sensitivity to SN-38 (A-1), mitoxantrone (A-2), and topotecan (A-3) of PA317, PA/WT, PA/V12M, and PA/Q141K cells. B, sensitivity to SN-38 (B-1), mitoxantrone (B-2), and topotecan (B-3) of PA317, PA/WT, and PA/Δ315-6 cells. •, PA317; ○, PA/WT; ▵, PA/V12M; □, PA/Q141K; ⋄, PA/Δ315-6.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    Intracellular topotecan uptake of BCRP-transfected PA317 cells. PA317 cells transfected with wild-type, G34A, C421A, and 944–949-deleted BCRP cDNAs were termed PA/WT, PA/V12M, PA/Q141K, and PA/Δ315-6, respectively. Cells were incubated for 30 min with (———) or without (······) 30 μm topotecan, washed, and topotecan uptake was measured by FACS. In parental PA317 cells, a fluorescence peak shift to the right after the incubation with topotecan indicates cellular uptake of topotecan, whereas only marginal shifts occurred in PA/WT, PA/V12M, and PA/Δ315-6 cells. There was a stronger fluorescence peak shift to the right in PA/Q141K cells than the other transfectants (arrow).

Tables

  • Figures
  • Table 1

    BCRP cDNA variants identified in this study

    VariantAmino acid changeCell line
    G34AVal-12 to MetMCF-7a
    C421AGln-141 to LysMDA-MB-231a
    A549a
    HCT-116a
    Deletion of 944–949Deletion of Ala-315 and Thr-316MCF-7
    A549
    HT-29
    SK-OV-3
    • ↵a Heterozygous allele.

  • Table 2

    IC50a (ng/ml) of BCRP-transfected PA317 cells

    PA317PA/WTPA/V12MPA/Q141KPA/Δ315-6
    SN-382.598983055
    Mitoxantrone0.0600.580.630.250.42
    Topotecan17>200>200100190
    • ↵a IC50s (drug dose causing 50% inhibition of cell growth) were determined from cell growth curves in each experiment.

  • Table 3

    Frequencies of G34A, C376T, and C421A polymorphisms of the BCRP gene in the general Japanese population

    Wild-typeHeterozygousHomozygousTotal
    G34A19 (66%)9 (31%)1 (3%)29
    C376Ta121 (98%)3 (2%)0 (0%)124
    C421A67 (54%)48 (39%)9 (7%)124
    • ↵a C376T polymorphism in exon 4 substitutes stop codon for Gln-126.

PreviousNext
Back to top
Molecular Cancer Therapeutics: 1 (8)
June 2002
Volume 1, Issue 8
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
C421A Polymorphism in the Human Breast Cancer Resistance Protein Gene Is Associated with Low Expression of Q141K Protein and Low-Level Drug Resistance 1 Supported in part by grants from the Ministry of Education, Culture, Sports, Science and Technology, …
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
C421A Polymorphism in the Human Breast Cancer Resistance Protein Gene Is Associated with Low Expression of Q141K Protein and Low-Level Drug Resistance 1 Supported in part by grants from the Ministry of Education, Culture, Sports, Science and Technology, the Ministry of Health, Labour and Welfare, Japan, and the Virtual Research Institute of Aging of Nippon Boehringer Ingelheim.1
Yasuo Imai, Minoru Nakane, Kumie Kage, Satomi Tsukahara, Etsuko Ishikawa, Takashi Tsuruo, Yoshio Miki and Yoshikazu Sugimoto
Mol Cancer Ther June 1 2002 (1) (8) 611-616;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
C421A Polymorphism in the Human Breast Cancer Resistance Protein Gene Is Associated with Low Expression of Q141K Protein and Low-Level Drug Resistance 1 Supported in part by grants from the Ministry of Education, Culture, Sports, Science and Technology, the Ministry of Health, Labour and Welfare, Japan, and the Virtual Research Institute of Aging of Nippon Boehringer Ingelheim.1
Yasuo Imai, Minoru Nakane, Kumie Kage, Satomi Tsukahara, Etsuko Ishikawa, Takashi Tsuruo, Yoshio Miki and Yoshikazu Sugimoto
Mol Cancer Ther June 1 2002 (1) (8) 611-616;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers
  • Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy: Disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non–small cell lung cancer cells (H1299)
  • Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells
Show more Article
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement